Half-year report · Q2
4572.TEDINET S100U5Y7
Period2024-01-01 → 2024-06-30
Filed2024-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥316m | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥1.6bn | 2023-01-01 → 2023-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥501m | 2023-01-01 → 2023-06-30 | Cons. | Net sales |
| Operating income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | −¥864m | 2023-01-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-01-01 → 2023-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥868m | 2023-01-01 → 2023-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥869m | 2023-01-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥886m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.1bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | −¥886m | 2023-01-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥3.7bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥4.3bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥4.6bn | at 2023-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥470m | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥472m | at 2023-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥3.9bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥4.1bn | at 2023-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.0bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥3.0bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2022-12-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥222m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.7bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥939m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥7m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11m | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7m | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥279m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.2bn | 2023-01-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-63.25 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-68.62 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-53.81 | 2023-01-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 87.2% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.9% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 8
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥1.1bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥316m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥316m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥24m |
| jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | −¥1.0bn |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue | 2023-01-01 → 2023-06-30 | ¥501m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | revenue external | 2023-01-01 → 2023-06-30 | ¥501m |
| jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segment | segment profit | 2023-01-01 → 2023-06-30 | ¥169m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 417
| Item | Context | Value | Unit |
|---|---|---|---|
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Material matters relating to going concern etc business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所 グロース市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)(注）1 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)MSIP CLIENT SECURITIES（常任代理人 モルガン・スタンレーMUFG証券株式会社） | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | 25 CABOT SQUARE, CANARY WHARF, LONDON E14 4QA, U.K. | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)小野薬品工業株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)大阪市中央区道修町2丁目1-5 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)上原 俊彦 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)吉野 公一郎 | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)大阪府吹田市 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | 25 BANK STREET, CANARY WHARF LONDON E14 5JP, U.K. | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)堀田 和男 | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)愛知県岡崎市 | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)野村證券株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都中央区日本橋1丁目13番1号 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | AIB INTERNATIONAL CENTRE P.O. BOX 518 IFSC DUBLIN, IRELAND | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)鈴木 隆啓 | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Original text (Japanese)愛知県名古屋市中区 | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)小川 義水 | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)東京都千代田区 | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)自己保有株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準的となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)カルナバイオサイエンス株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)神戸市中央区港島南町一丁目5番5号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Original text (Japanese)当社の中間連結財務諸表は、第一種中間連結財務諸表であります。 | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |